Opioid use disorder (OUD) frequently begins in adolescence and young adulthood. Intervening early with pharmacotherapy is recommended by major professional organizations. No prior national studies have examined the extent to which adolescents and young adults (collectively termed youth) with OUD receive pharmacotherapy.
D rug overdose deaths in the United States-the majority of which are caused by prescription opioids and heroinhave reached an unprecedented level, having tripled from 2000 to 2014 and surpassed annual mortality from motor vehicle crashes. [1] [2] [3] [4] [5] Hospitalizations and emergency department visits for overdose, 6,7 drug treatment admissions, 8 and new hepatitis C infections 9 related to opioids have risen dramatically over a similar timeframe. Risk for opioid use disorder (OUD) frequently begins in adolescence and young adulthood, with 7.8% of high school seniors reporting lifetime nonmedical prescription opioid use.
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Two-thirds of individuals in treatment for OUD report that their first use was before age 25 years, and one-third report that it was before 18 years. 8 Intervening early in the development of OUD is critical for preventing premature death and lifelong harm. 11 However, only 1 in 12 adolescents and young adults (collectively termed youth) 12 who need care for any type of addiction receive treatment. 13 Compounding this situation, black and Hispanic youth are even less likely than white youth to receive addiction treatment.
14,15
Buprenorphine, a partial opioid agonist, and naltrexone, an opioid antagonist, prevent relapse and overdose among youth with OUD. [16] [17] [18] [19] [20] The US Food and Drug Administration (FDA) approved buprenorphine for adolescents (≥16 years) in 2003. Oral naltrexone has been FDA-approved for adults (≥18 years) since 1984, and the FDA approved a long-acting injectable formulation in 2010. Unlike methadone, both buprenorphine and naltrexone can be offered in primary care and subspecialty settings in the United States. 21 However, there is a widespread shortage of physicians who have received the waiver certification required to prescribe buprenorphine and, of all physicians who are certified in the United States, only 1% are pediatricians. 22 Naltrexone does not require special prescriber certification and is not an opioid agonist, and thus may be viewed more favorably by some physicians 23 ; nonetheless, it has historically been less commonly prescribed for adults than buprenorphine. 24 Despite the much earlier documented efficacy and FDA approval of buprenorphine and naltrexone, the American Academy of Pediatrics did not release a policy statement calling for the use of pharmacotherapy for youth with OUD until August 2016. 25 The absence of such a statement may have delayed adoption of pharmacotherapy by pediatricians, even despite preexisting recommendations from the Substance Abuse and Mental Health Services Administration 23 and amidst a worsening youth opioid epidemic. 6 We know of no large-scale studies to date that have examined what percentage of youth with OUD receive pharmacotherapy. Understanding which youth receive medications, which medication (buprenorphine or naltrexone) they receive, and how medication dispensing varies by sociodemographic characteristics is critical to inform the expansion of addiction treatment services, which is a national priority in the United States.
26, 27 We identified trends and disparities in pharmacotherapy for youth during a time of escalating prevalence of OUD.
Methods

Data Source
We used deidentified Optum data (OptumInsight), which contain enrollment records and all inpatient, outpatient, emergency department, and pharmacy claims from a large US commercial health insurer with members in all 50 states and Washington, DC. All members in the data set had prescription drug coverage. The Harvard Pilgrim Health Care Institutional Review Board approved the study with waiver of informed consent.
Sample Selection
The primary analytic sample included all youth aged 13 to 25 years who received a diagnosis of OUD between January 
Variables of Interest
Our primary outcome of interest was receipt of buprenorphine (formulated as buprenorphine or buprenorphinenaloxone combination) or naltrexone (in its oral short-acting or intramuscular extended-release formulation) within 6 months of the first observed OUD diagnosis. Although clinical practice guidelines recommend considering pharmacotherapy as soon as possible after OUD diagnosis, 23,25 we examined a 6-month timeframe to allow for any delay in linking youth to treatment services. We identified pharmacy claims that included a National Drug Code for buprenorphine (excluding the transdermal buprenorphine patch marketed exclusively for pain control) or naltrexone (eTable 1 in the Supplement). Since intramuscular extended-release naltrexone is often administered in health care settings (rather than being prescribed), an individual was also considered to have received naltrexone if a claim contained Healthcare Common Procedure Coding System code J2315 (naltrexone, depot form).
Each individual was labeled with a unique identifier and was included in the analytic sample only once at the time of the first observed diagnosis.
Covariates of interest included sex, age at OUD diagnosis, race/ethnicity, geographic region (ie, metropolitan vs nonmetropolitan), neighborhood educational level, and neighborhood poverty level, using previously established cutoff levels. [29] [30] [31] To identify race/ethnicity, we used a combination of 2000 US Census 31 neighborhood characteristics and surname analysis, which is a validated approach with high positive predictive value.
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Statistical Analysis
Using the entire sample of 13-to 25-year-old youth with 6 or more months of continuous enrollment, we calculated annual diagnosis rates (ie, number of first observed diagnoses of OUD in a year divided by total person-years contributed) according to age group (13-15, 16-17, 18-20, and 21-25 years). For all subsequent analyses, we limited the sample to youth who had received an OUD diagnosis. We then identified the proportion of youth who received buprenorphine or naltrexone within 6 months of the diagnosis. Among youth who received pharmacotherapy, we examined linear time trends in receipt of buprenorphine compared with naltrexone, introducing splines with 2 knots defined a priori corresponding to the FDA approval of buprenorphine and buprenorphine-naltrexone in October 2002, and of intramuscular extended-release naltrexone in October 2010. We then identified differences between youth who received buprenorphine compared with naltrexone. Where cell counts were less than 10, categories were excluded or collapsed together to protect confidentiality.
To compare characteristics of youth who did and did not receive pharmacotherapy, we used logistic regression to identify associations between study covariates and medication receipt. We subsequently generated a multivariable model including all study covariates, given the known association of each covariate with access to addiction treatment [33] [34] [35] ;w e additionally adjusted for year as an indicator variable to account for secular trends. Using this multivariable model and the margins command in Stata, we then calculated the adjusted probability of receiving pharmacotherapy.
To understand the effect of considering a different timeframe for receipt of pharmacotherapy after OUD diagnosis, we conducted sensitivity analyses in which the outcome of interest was receipt of a medication within 3 and 12 months (compared with 6 months) of OUD diagnosis and requiring 3 or more and 12 or more months of continuous enrollment, respectively. We repeated the multivariable model for both timeframes. Analyses were conducted from April 25 to December 31, 2016, using Stata, version 13.1 (StataCorp LP). All statistical tests were 2-sided and considered significant at P < .05.
Results
Between January 1, 2001, and June 30, 2014, there were 9 710 131 youth aged 13 to 25 years in the Optum database with 6 or more months of continuous enrollment and, of these youth, 20 822 (0.2%) met the criteria for an OUD diagnosis. Median time observed prior to first OUD diagnosis was 20 months per individual (interquartile range [IQR], 7-45 months). Figure 1 shows the diagnosis rate by calendar year according to age. The overall diagnosis rate increased with each subsequent study year, rising nearly 6-fold, from 0.26 per 100 000 person-years in 2001 to 1.51 per 100 000 person-years in 2014. This rise was driven primarily by increases in diagnoses among young adults (≥18 years), although diagnosis rates for all age categories increased over the study period. Table 1 displays the characteristics of the sample. Among youth with OUD, 65.8% were male and mean age (SD) was 21.0 (2.5) years at the time of diagnosis; most youth with OUD came from a predominantly non-Hispanic white neighborhood (82.2%). Compared with the overall sample, youth with OUD were more likely to be male or from a non-Hispanic white neighborhood, metropolitan area, high educational level neighborhood, low poverty level neighborhood, or the Northeast.
Overall, 5580 (26.8%) youth with OUD received either buprenorphine or naltrexone within 6 months of their first observed diagnosis. Table 2 displays the percentage of youth who received a medication according to sociodemographic characteristics. In the multivariable model, factors significantly associated with decreased odds of medication receipt included younger age, female sex, non-Hispanic black race, Hispanic ethnicity, and low-middle neighborhood poverty level. Figure 3 shows time trends in the adjusted probability of receiving a medication according to age group. Increases were greatest between 2003 and 2007, with larger increases observed among older youth compared with younger individuals. Table 3 compares the characteristics of youth who received buprenorphine compared with those who received naltrexone. Youth were less likely to receive buprenorphine than naltrexone if they were younger or female. They were more likely to receive buprenorphine if they were from a nonmetropolitan area; low-middle or low educational level neighborhood; low-middle, high-middle, or high poverty level neighborhood; or from the Midwest.
Sensitivity analyses examining medication receipt within 3 and 12 months are reported in eTables 2 and 3 in the Supplement, respectively. Although effect sizes across age, sex, and race/ethnicity strata using 3-and 12-month timeframes were similar to those for a 6-month timeframe, adjusted ORs were not significant for non-Hispanic black youth, using a 3-month timeframe, or for non-Hispanic black youth and Hispanic youth, using a 12-month timeframe.
Discussion
In this large national study of buprenorphine and naltrexone dispensing among commercially insured youth with OUD, we found that only 1 in 4 youth received pharmacotherapy within 6 months of diagnosis during the 2001-2014 study period. From 2002 (when buprenorphine was introduced) to 2009, the percentage of youth receiving medication increased more than 10-fold, but subsequently declined amidst escalating OUD diagnosis rates. The odds of receiving pharmacotherapy were lower with younger age and among females compared with males, and non-Hispanic black and Hispanic youth compared with white youth. Overall, buprenorphine was dispensed 8 times more often than naltrexone. Naltrexone was more commonly dispensed to younger individuals and females and to youth in metropolitan areas, higher educational level neighborhoods, and lower poverty level neighborhoods.
Only a minority of youth with OUD received pharmacotherapy, thus revealing a potentially critical treatment gap. This finding reconfirms the 2016 surgeon general's report that highlighted the large number of youth with untreated addiction 27 and also supports the recent policy statement from the American Academy of Pediatrics calling for expanded access to medi- working to expand access to pharmacotherapy for youth ensure that services are disseminated in a way that addresses, rather than worsens, racial/ethnic and sex disparities. Since most youth with OUD do not receive medications in a timely manner, strategies to improve access to evidencebased treatment for adolescents are needed. One strategy is to increase the number of pediatric addiction subspecialists. 43 With the recent recognition of addiction medicine by the American Board of Medical Specialties, pediatricians and family physicians have new opportunities to pursue board certification and are well poised to disseminate developmentally appropriate services for youth. 44 However, since there are unlikely to be sufficient pediatric addiction subspecialists to address the large number of youth with OUD, an additional strategy is to implement pharmacotherapy in pediatric primary care. 25, 44 This approach is increasingly used to treat adults with OUD 45, 46 and is recommended by the American Academy of Pediatrics.
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Limitations
There are several limitations to this study. First, we could not assess the severity of individuals' addiction. It is possible that older youth or other demographic groups had more severe OUD for which pharmacotherapy was more strongly indicated. Second, our approach likely underestimated the number of youth with OUD since we relied on billing diagnoses. The actual proportion of youth with OUD who receive pharmacotherapy may be even lower than reported herein because many youth go undiagnosed or clinicians may be reluctant to code this sensitive diagnosis. 47 Third, we were unable to assess receipt of methadone. Since provision of methadone to adolescents younger than 18 years is highly restricted, 48 we do not anticipate that many underage youth received methadone; some youth 18 years or older may have received methadone from publicly funded programs. 15,49 Fourth, our sample included only commercially insured youth; thus, generalizability to populations without private health insurance is unclear. Recent data suggest that adults without health insurance are unlikely to receive pharmacotherapy for OUD, whereas adults with public health insurance may be as likely to receive pharmacotherapy as those with private insurance.
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Conclusions
We observed improvements in the percentage of youth receiving pharmacotherapy for OUD between 2001 and 2014, but noted an apparent decrease after 2009 amidst an escalating diagnosis rate and despite the FDA approval of long-acting injectable naltrexone in 2010. There remains substantial room for improvement in the provision of pharmacotherapy to youth with OUD. Both the American Academy of Pediatrics and the 2016 surgeon general's report highlight that intervention early in the life course of youth addiction is critical for preventing progression to more severe disease, 25 ,27 yet our data indicate that medications are underutilized for youth. Adolescents might especially be underserved in the current treatment environment, and female, non-Hispanic black, and Hispanic 
